SUSTAIN 340B Act and Legislative Developments in Healthcare

This week, significant legislative activity in the healthcare sector included the introduction of the SUSTAIN 340B Act by a bipartisan group of senators. Aimed at reforming the 340B drug pricing program, the bill proposes maintaining point-of-purchase discounts and enhancing oversight of involved entities through an independent data clearinghouse. The legislation seeks to sunset the proposed 340B Rebate Model Pilot Program within a year while establishing contract pharmacy usage with specific registration and audit processes.

The SUSTAIN 340B Act introduces stricter compliance requirements, including limitations on eligible patients and child site usage. It also imposes increased obligations for reporting and transparency, setting a higher standard for regulatory adherence across the board. These changes are designed to streamline the program's operations while ensuring accountability for all stakeholders.

Senate Advances Continuing Resolution

Separately, the Senate has advanced a continuing resolution (CR) intended to maintain government funding at current levels until December 11, 2026. This CR postpones the finalization of the Office of Management and Budget's proposed Uniform Guidance for federal grants, addressing concerns over oversight and grant availability. It reallocates $21.4 million from the Medicare Improvement Fund for disaster relief in the Northern Mariana Islands, reflecting a broader legislative effort to ensure efficient use of resources.

The House passed its version of the CR, proposing funding through December 4, 2026, without language addressing the Uniform Guidance, necessitating reconciliation to prevent a government shutdown post-September 30, 2026. These differing timelines underline the need for swift negotiation and agreement to maintain government operations smoothly.

Medicaid Program Costs Under Scrutiny

In other discussions, a recent Senate Budget Committee hearing on Medicaid spotlighted rising program costs and potential inefficiencies. Committee members and witnesses, such as Dr. Brian Blase and Mr. Jonathan Ingram, critiqued Medicaid’s growth beyond projections, citing improper enrollments and the use of provider taxes. There was substantial debate on the impacts of reforms on Medicaid beneficiaries and healthcare providers, highlighting partisan differences over program integrity and access to care.

At a White House Fraud Task Force roundtable, Vice President J.D. Vance emphasized the need for legislative support to enhance fraud prevention efforts. The administration advocates for increased data sharing between federal and state entities to curb fraud in Medicaid and Medicare. The task force's findings indicate the critical role of technology, including AI, in identifying fraudulent activities before funds are distributed. These developments underscore the ongoing focus on improving oversight, efficiency, and sustainability within healthcare resources.